Overview Dividends

(HCA) HCA Holdings - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40412C1018

Hospital, Outpatient, Surgery, Imaging, Behavioral

Health Care Facilities
Market Cap in USD: 111,645m

IPO / Inception: 2011-03-10
Return 12m vs S&P 500: 35.3%

EPS (Earnings per Share)

EPS CAGR: 12.87%
EPS Trend: 84.9%

Last SUE: 3.47
Qual. Beats: 3

Revenue

Rev. CAGR: 6.63%
Rev. Trend: 97.9%

Last SUE: 1.97
Qual. Beats: 1

Dividends

Dividend Yield	0.61%
Yield on Cost 5y	1.83%
Yield CAGR 5y	36.07%
Payout Consistency	53.8%
Payout Ratio	10.9%

Risk via 5d forecast
Volatility	24.2%
Value at Risk 5%th	39.0%
Relative Tail Risk	-1.89%

Reward TTM
Sharpe Ratio	1.66
Alpha	49.45
CAGR/Max DD	0.92

Character TTM
Hurst Exponent	0.617
Beta	0.271
Beta Downside	0.371

Drawdowns 3y
Max DD	28.45%
Mean DD	8.49%
Median DD	6.00%

Description: HCA HCA Holdings December 02, 2025

HCA Healthcare, Inc. (NYSE:HCA) operates a nationwide network of acute-care hospitals and a broad suite of outpatient facilities-including ambulatory surgery centers, urgent-care clinics, imaging centers, and behavioral health hospitals-providing services from inpatient and intensive care to outpatient diagnostics and rehabilitation.

As of FY 2023, HCA reported $20.1 billion in revenue with an adjusted EBITDA margin of roughly 15%, driven by a 4.2% year-over-year increase in inpatient admissions and a 3.8% rise in outpatient volume. The company’s average occupancy rate sits near 71%, slightly above the industry average of 68%, reflecting strong demand for both acute and specialty services.

Key macro-drivers for HCA include the aging U.S. population, which fuels higher utilization of cardiac and orthopedic procedures, and ongoing Medicare-DRG reimbursement reforms that pressure margins. Additionally, labor shortages in nursing and allied health professions remain a cost headwind, prompting the firm to invest in automation and workforce retention programs.

For a deeper quantitative view, you might explore the ValueRay platform’s hospital profitability metrics.

Piotroski VR‑10 (Strict, 0-10) 7.5

Net Income (6.38b TTM) > 0 and > 6% of Revenue (6% = 4.46b TTM)

FCFTA 0.14 (>2.0%) and ΔFCFTA 3.66pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -3.51% (prev 2.53%; Δ -6.04pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.21 (>3.0%) and CFO 12.84b > Net Income 6.38b (YES >=105%, WARN >=100%)

Net Debt (45.35b) to EBITDA (15.00b) ratio: 3.02 <= 3.0 (WARN <= 3.5)

Current Ratio 0.85 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (242.5m) change vs 12m ago -6.72% (target <= -2.0% for YES)

Gross Margin 15.64% (prev 15.08%; Δ 0.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 124.8% (prev 117.1%; Δ 7.69pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.23 (EBITDA TTM 15.00b / Interest Expense TTM 2.20b) >= 6 (WARN >= 3)

Altman Z'' 0.65

(A) -0.04 = (Total Current Assets 15.29b - Total Current Liabilities 17.90b) / Total Assets 59.75b

(B) -0.08 = Retained Earnings (Balance) -5.03b / Total Assets 59.75b

(D) -0.09 = Book Value of Equity -5.33b / Total Liabilities 61.91b

Total Rating: 0.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.08

1. Piotroski 7.50pt

2. FCF Yield 5.16%

3. FCF Margin 10.89%

4. Debt/Equity -8.69

5. Debt/Ebitda 3.02

6. ROIC - WACC (= 17.40)%

7. RoE -161.9%

8. Rev. Trend 97.85%

9. EPS Trend 84.87%

What is the price of HCA shares?

As of December 30, 2025, the stock is trading at USD 474.02 with a total of 792,584 shares traded.
Over the past week, the price has changed by +0.42%, over one month by -5.62%, over three months by +12.78% and over the past year by +60.03%.

Is HCA a buy, sell or hold?

HCA Holdings has received a consensus analysts rating of 4.08. Therefore, it is recommended to buy HCA.

Strong Buy: 13
Buy: 2
Hold: 9
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the HCA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	482	1.7%
Analysts Target Price	482	1.7%
ValueRay Target Price	621.6	31.1%

HCA Fundamental Data Overview December 27, 2025

Market Cap USD = 111.65b (111.65b USD * 1.0 USD.USD)
P/E Trailing = 18.4505
P/E Forward = 16.129
P/S = 1.5012
P/B = 293.44
P/EG = 1.2731
Beta = 1.367
Revenue TTM = 74.37b USD
EBIT TTM = 11.53b USD
EBITDA TTM = 15.00b USD
Long Term Debt = 38.40b USD (from longTermDebt, last quarter)
Short Term Debt = 6.11b USD (from shortTermDebt, last quarter)
Debt = 46.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 45.35b USD (from netDebt column, last quarter)
Enterprise Value = 157.00b USD (111.65b + Debt 46.35b - CCE 997.0m)
Interest Coverage Ratio = 5.23 (Ebit TTM 11.53b / Interest Expense TTM 2.20b)
FCF Yield = 5.16% (FCF TTM 8.10b / Enterprise Value 157.00b)
FCF Margin = 10.89% (FCF TTM 8.10b / Revenue TTM 74.37b)
Net Margin = 8.57% (Net Income TTM 6.38b / Revenue TTM 74.37b)
Gross Margin = 15.64% ((Revenue TTM 74.37b - Cost of Revenue TTM 62.74b) / Revenue TTM)
Gross Margin QoQ = 15.47% (prev 15.95%)
Tobins Q-Ratio = 2.63 (Enterprise Value 157.00b / Total Assets 59.75b)
Interest Expense / Debt = 1.21% (Interest Expense 561.0m / Debt 46.35b)
Taxrate = 21.06% (516.0m / 2.45b)
NOPAT = 9.10b (EBIT 11.53b * (1 - 21.06%))
Current Ratio = 0.85 (Total Current Assets 15.29b / Total Current Liabilities 17.90b)
Debt / Equity = -8.69 (negative equity) (Debt 46.35b / totalStockholderEquity, last quarter -5.33b)
Debt / EBITDA = 3.02 (Net Debt 45.35b / EBITDA 15.00b)
Debt / FCF = 5.60 (Net Debt 45.35b / FCF TTM 8.10b)
Total Stockholder Equity = -3.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.67% (Net Income 6.38b / Total Assets 59.75b)
RoE = -161.9% (negative equity) (Net Income TTM 6.38b / Total Stockholder Equity -3.94b)
RoCE = 33.45% (EBIT 11.53b / Capital Employed (Equity -3.94b + L.T.Debt 38.40b))
RoIC = 22.63% (NOPAT 9.10b / Invested Capital 40.21b)
WACC = 5.23% (E(111.65b)/V(157.99b) * Re(7.01%) + D(46.35b)/V(157.99b) * Rd(1.21%) * (1-Tc(0.21)))
Discount Rate = 7.01% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -5.44%
[DCF Debug] Terminal Value 80.13% ; FCFE base≈7.21b ; Y1≈8.25b ; Y5≈11.48b
Fair Price DCF = 869.4 (DCF Value 198.39b / Shares Outstanding 228.2m; 5y FCF grow 16.94% → 3.0% )
EPS Correlation: 84.87 | EPS CAGR: 12.87% | SUE: 3.47 | # QB: 3
Revenue Correlation: 97.85 | Revenue CAGR: 6.63% | SUE: 1.97 | # QB: 1
EPS next Quarter (2026-03-31): EPS=7.17 | Chg30d=-0.026 | Revisions Net=+5 | Analysts=12
EPS next Year (2026-12-31): EPS=29.72 | Chg30d=-0.030 | Revisions Net=+15 | Growth EPS=+7.3% | Growth Revenue=+4.5%

Additional Sources for HCA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle